Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

A recent study suggests that Eli Lilly's new weight-loss medication helped individuals lose significant amounts of ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

GLP-1s have been a hot topic, now people are raising concerns about the side effects. From loose skin and dull complexions to hair loss and more. Aesthetic ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

Share on Twitter Print Share by Email Share Back to top In spring 2025, the Food and Drug Administration (FDA) resolved and ended the ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...